Cougar Biotechnology to Present at Citi Biotech Day

LOS ANGELES--(Business Wire)--
Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that Alan
H. Auerbach, Chief Executive Officer and President of Cougar, will
present at the 3rd Annual Citi Biotech Day on Monday, September 8, at
11:15 a.m. EDT at the Citi Executive Conference Center in New York
City. Mr. Auerbach will provide a company overview and update on the
status of Cougar's current clinical development programs.

Interested investors may access a live audio webcast by visiting
the Investor Relations section of the Company's Web site at
www.cougarbiotechnology.com. The presentation will be archived on the
Web site and available for 30 days.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology
company established to in-license and develop clinical stage drugs,
with a specific focus on the field of oncology. Cougar's oncology
portfolio includes CB7630, a targeted inhibitor of the
17alpha-hydroxylase/c17,20 lyase enzyme, which is currently being
tested in Phase III clinical trials in prostate cancer; CB3304, an
inhibitor of microtubule dynamics, which is currently in a Phase I
trial in multiple myeloma; and CB1089, an analog of vitamin D, which
has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at
www.cougarbiotechnology.com.

Cougar Biotechnology, Inc.
+1-310-943-8040
Alan H. Auerbach, Chief Executive Officer and President
ahauerbach@cougarbiotechnology.com
Mariann Ohanesian, Director of Investor Relations
mohanesian@cougarbiotechnology.com
or
Russo Partners, LLC
David Schull, +1-212-845-4271
David.schull@russopartnersllc.com
Andreas Marathovouniotis, +1-212-845-4235
Andreas.marathis@russopartnersllc.com

Copyright Business Wire 2008